Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis

Rheumatology

Volumn 46, Issue 3, 2007, Pages 439-441

  Gadsby, K ^a   Deighton, Chris ^a  

^a DERBYSHIRE ROYAL INFIRMARY   (United Kingdom)

Author keywords

Ankylosing spondyltitis; Biological therapy; Guidelines

Indexed keywords

ANALGESIC AGENT; ETANERCEPT; HEMOGLOBIN; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; BLOOD CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUPUS VULGARIS; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VISUAL ANALOG SCALE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BLOOD SEDIMENTATION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PAIN MEASUREMENT; PATIENT SELECTION; PRACTICE GUIDELINES; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33847365774     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel430     Document Type: Article

References (17)

1. Wilkinson M, Bywaters E. Clinical features and course of ankylosing spondylitis as seen in a follow up of 222 hospital referred cases. Ann Rheum Dis 1958; 17:209-28.
2. Brophy S, Calin A. Definition of disease flare in ankylosing spondylitis: The patients' perspective. J Rheumatol 2002;29:954-8.
3. Mascerenhas RF, Davis MJ, Robertson LP. Eligibility for anti-TNF therapy in ankylosing spondylitis: What's the real situation? Rheumatology 2005; 43(Suppl 2):126.
4. Wolfe F, Michaud K, DeWitt EM. Why results of clinical trials and observational studies of anti-tumour necrosis factor (anti-TNF) therapy differ: Methodological and interpretive issues. Ann Rheum Dis 2004;63(Suppl II):iI13-7.
5. Keat A, Barkham N, Bhalla A et al. BSR guidelines for prescribing TNF-α blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology 2005;44:939-47.
6. Ledingham J, Deighton CM. Update of BSR guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology 2005;44:157-63.
7. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
8. Braun J, Davis J, Dougados M et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20.
9. der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
10. Kavanaugh A, Tutuncu Z, Catalan Sanchez T. Update on anti-tumour necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. Curr Opin Rheumatol 2006;18:347-53.
11. Henderson C, Davis JC. Drug insight: Anti-tumour-necrosis-fatcor therapy for ankylosing spondylitis. Nat Clin Pract Rheumatol 2006;2:211-8.
12. Baraliakos X, Brandt J, Listing et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 2005;53:856-63.
13. Davis JC, van der Heijde DM, Braun J et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005;64:1557-1562.
14. Delaunay C, Farrenq V, Marini-Portugal A et al. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol 2005;32:2183-5.
15. Gomez-Reino JJ, Carmona L for the BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29.
16. Hyrich KL, Silman AJ, Lunt M, Watson K, Symmons D. BSR Biologics Register. Influence of response and adverse event rates to a first anti-TNF-α agent on the outcome of switching to a second agent: Results from British Society of Rheumatology Biologics Register. Arthritis Rheum 2005;9(Suppl):S339.
17. Buch MH, Emery P. Nonresponse to tumour necrosis factor antagonists - is there any point in re-treatment? Nat Clin Pract Rheumatol 2006;2:288-9.